The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Phase 1 study of the investigational CD228 x 4-1BB costimulatory antibody Anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
Dummer R, Daud A, Eigentler T, Evans TRJ, Henry JT, Hodi FS, Miller WH, Robert C, Saibil S, Tachiki L, Nayeri M, Xing B, Mehnert J
CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein | September 13, 2024 | ESMO 2024
C5871001 | NCT05571839
